





The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.


Respectfully submitted,

Jamie L. Greene  
Reg. No. 32,467

KILPATRICK STOCKTON LLP  
1100 Peachtree Street, Suite 2800  
Atlanta, Georgia 30309-4530  
(404) 815-6500  
Our Docket: 05213-0880 (43170-249874)

**RECEIVED**  
AUG 15 2002  
TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (43170-249874)

Sheet	1	of	6
-------	---	----	---

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	1	60/80728		MIXSON, James A.	06/27/2000	

**RECEIVED**

AUG 15 2002

TECH CENTER 1600/2900

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (43170-249874)

Sheet 2 of 6


**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS****RECEIVED****AUG 15 2002****TECH CENTER 1600/2900**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	2	<p><b>Author:</b> Title: Chapter 12: Vectors for Gene Therapy</p> <p><b>Publ:</b> <u>Current Protocols in Human Genetics</u> <b>Vol/Iss:</b> <b>Pages:</b> <b>Date:</b> 1997</p>
	3	<p><b>Author:</b> BOUSSIF, O. et al. <b>Title:</b> A versatile vector for gene and oligonucleotide transfer into cells in culture and <i>in vivo</i>: Polyethylenimine</p> <p><b>Publ:</b> <u>Proc. Natl. Acad. Sci. USA</u> <b>Vol/Iss:</b> 92 <b>Pages:</b> 7297-7301 <b>Date:</b> 08/1995</p>
	4	<p><b>Author:</b> CALOS, MICHELE P. <b>Title:</b> The potential of extrachromosomal replicating vectors for gene therapy</p> <p><b>Publ:</b> <u>TIG</u> <b>Vol/Iss:</b> 12 (11) <b>Pages:</b> 463-466 <b>Date:</b> 11/1996</p>
	5	<p><b>Author:</b> CHEN, P. et al. <b>Title:</b> Genetic Mechanisms of Tumor Suppression by the Human p53 Gene</p> <p><b>Publ:</b> <u>Science</u> <b>Vol/Iss:</b> 250 <b>Pages:</b> 1576-1579 <b>Date:</b> 12/1990</p>
	6	<p><b>Author:</b> CHENG, PI-WAN <b>Title:</b> Receptor Ligand-Facilitated Gene Transfer: Enhancement of Liposome-Mediated Gene Transfer and Expression by Transferrin</p> <p><b>Publ:</b> <u>Human Gene Therapy</u> <b>Vol/Iss:</b> 7 <b>Pages:</b> 275-282 <b>Date:</b> 02/10/199</p>
	7	<p><b>Author:</b> DARDIK, R. et al. <b>Title:</b> The structure of endothelial cell thrombospondin - Characterization of the heparin-binding domains</p> <p><b>Publ:</b> <u>Eur J Biochem</u> <b>Vol/Iss:</b> 168 (2) <b>Pages:</b> 347-355 <b>Date:</b> 10/15/198</p>
	8	<p><b>Author:</b> DEBS, R.J. et al. <b>Title:</b> Regulation of Gene Expression <i>in Vivo</i> by Liposome-mediated Delivery of a Purified Transcription Factor</p> <p><b>Publ:</b> <u>The Journal of Biological Chemistry</u> <b>Vol/Iss:</b> 265 (18) <b>Pages:</b> 10189-10192 <b>Date:</b> 06/25/199</p>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO) Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/APP

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (43,781,49874)

Sheet 3 of 6

RECEIVED

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

AUG 15 2002


TECH CENTER 1600/2900

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number, publisher, city and/or country where published			
	9	<b>Author:</b> DIXIT, V.M. et al. <b>Title:</b> A monoclonal antibody against human thrombospondin inhibits platelet aggregation <b>Publ:</b> Proc. Natl. Acad. Sci. USA <b>Vol/Iss:</b> 82 <b>Pages:</b> 3472-3476 <b>Date:</b> 05/1985			
	10	<b>Author:</b> FAN et al. <b>Title:</b> Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy <b>Publ:</b> Trends in Pharmacological Sciences <b>Vol/Iss:</b> 16 (2) <b>Pages:</b> 57-66 <b>Date:</b> 02/95			
	11	<b>Author:</b> FIDLER et al. <b>Title:</b> The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis <b>Publ:</b> Cell <b>Vol/Iss:</b> 79(2) <b>Pages:</b> 185-188 <b>Date:</b> 10/21/94			
	12	<b>Author:</b> FUJIWARA, T. et al. <b>Title:</b> Induction of Chemosensitivity in Human Lung Cancer Cells <i>in Vivo</i> by Adenovirus-mediated Transfer of the Wild-Type p53 Gene <b>Publ:</b> Cancer Research <b>Vol/Iss:</b> 54 <b>Pages:</b> 2287-2291 <b>Date:</b> 05/01/199			
	13	<b>Author:</b> GOLDMAN, C.K. et al. <b>Title:</b> In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer <b>Publ:</b> Nature Biotechnology <b>Vol/Iss:</b> 15 <b>Pages:</b> 462-466 <b>Date:</b> 05/1997			
	14	<b>Author:</b> HAWKINS, MICHAEL J. <b>Title:</b> Clinical trials of antiangiogenic agents M.D. <b>Publ:</b> Current Opinion in Oncology <b>Vol/Iss:</b> 7 <b>Pages:</b> 90-93 <b>Date:</b> 1995			
	15	<b>Author:</b> KING, RALPH P. Jr. <b>Title:</b> Novel Cancer Approach From Noted Scientist Hits Stumbling Block <b>Publ:</b> Wall Street Journal <b>Vol/Iss:</b> <b>Pages:</b> A1, A8 <b>Date:</b> 11/12/199			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff

Sheet 4 of 6

Attorney Docket Number 05213-0880 (1170-249-73)

RECEIVED

AUG 15 2002

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	16	<b>Author:</b> KOSFELD, M.D. et al.	<b>Title:</b> Identification of a New Cell Adhesion Motif in Two Homologous Peptides from the COOH-terminal Cell Binding Domain on Human Thrombospondin		
		<b>Publ:</b> The Journal of Biological Chemistry	<b>Vol/Iss:</b> 268 (12)	<b>Pages:</b> 8808-8814	<b>Date:</b> 1993
	17	<b>Author:</b> LESOON-WOOD, L.A. et al.	<b>Title:</b> Systemic Gene Therapy with p53 Reduces Growth and Metastases of a Malignant Human Breast Tumor in Nude Mice		
		<b>Publ:</b> Human Gene Therapy	<b>Vol/Iss:</b> 6	<b>Pages:</b> 395-405	<b>Date:</b> 04/1995
	18	<b>Author:</b> MAIONE, T.E. et al.	<b>Title:</b> Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Affinity for Heparin and Retains Potent Angiostatic Activity		
		<b>Publ:</b> Cancer Research	<b>Vol/Iss:</b> 51	<b>Pages:</b> 2077-2083	<b>Date:</b> 04/15/199
	19	<b>Author:</b> MARSHALL, ELIOT	<b>Title:</b> Gene Therapy's Growing Pains		
		<b>Publ:</b> Science	<b>Vol/Iss:</b> 269	<b>Pages:</b> 1050-1055	<b>Date:</b> 08/25/199
	20	<b>Author:</b> O'REILLY et al.	<b>Title:</b> Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth		
		<b>Publ:</b> Cell	<b>Vol/Iss:</b> 88	<b>Pages:</b> 277-285	<b>Date:</b> 01/24/97
	21	<b>Author:</b> PARK et al.	<b>Title:</b> Development of liposome- and anti-HER2 immunoliposomeplasmid complexes for efficient and selective gene therapy		
		<b>Publ:</b> Proceedings of the American Association for Cancer Research	<b>Vol/Iss:</b> 38	<b>Pages:</b> 342	<b>Date:</b> 03/1997
	22	<b>Author:</b> PASQUALINI, R. et al.	<b>Title:</b> $\alpha$ v Integrins as receptors for tumor targeting by circulating ligands		
		<b>Publ:</b> Nature Biotechnology	<b>Vol/Iss:</b> 15	<b>Pages:</b> 542-546	<b>Date:</b> 06/1997

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application No	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (43170-249874)

Sheet 5 of 6

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS****RECEIVED**

AUG 15 2002


TECH CENTER 1600/2900

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	23	<b>Author:</b> PASQUALINI, R. et al. <b>Title:</b> Organ targeting <i>in vivo</i> using phage display peptide libraries <b>Publ:</b> <u>Nature</u> <b>Vol/Iss:</b> 380 <b>Pages:</b> 364-166 <b>Date:</b> 03/28/199
	24	<b>Author:</b> SAIKI et al. <b>Title:</b> Inhibition of Tumor Angiogenesis by a Synthetic Cell-adhesive Polypeptide Containing the Arg-Gly-Asp (RGD) Sequence of Fibronectin, Poly(RGD) <b>Publ:</b> <u>Jpn. J. Cancer Research</u> <b>Vol/Iss:</b> 81 <b>Pages:</b> 668-675 <b>Date:</b> 1990
	25	<b>Author:</b> SHEIKH et al. <b>Title:</b> Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines <b>Publ:</b> <u>Oncogene</u> <b>Vol/Iss:</b> 11 <b>Pages:</b> 1899-1905 <b>Date:</b> 1995
	26	<b>Author:</b> TANAKA, T. et al. <b>Title:</b> Viral vector-mediated transductions of a modified platelet factor 3 cDNA inhibits angiogenesis and tumor growth <b>Publ:</b> <u>Nature Medicine</u> <b>Vol/Iss:</b> 3 <b>Pages:</b> 437-442 <b>Date:</b> 04/1997
	27	<b>Author:</b> WEINSTAT-SASLOW, D.L. et al. <b>Title:</b> Transfection of Thrombospondin 1 Complementary DNA into a Human Breast Carcinoma Cell Line Reduces Primary Tumor Growth, Metastatic Potential, and Angiogenesis <b>Publ:</b> <u>Cancer Research</u> <b>Vol/Iss:</b> 54 <b>Pages:</b> 6504-6511 <b>Date:</b> 1994
	28	<b>Author:</b> XU, M. et al. <b>Title:</b> In Vivo Gene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes <b>Publ:</b> <u>Molecular Genetics and Metabolism</u> <b>Vol/Iss:</b> 64 <b>Pages:</b> 001-005 <b>Date:</b> 1998
	29	<b>Author:</b> XU, M. et al. <b>Title:</b> Gene Therapy with P53 and a Fragment of Thrombospondin 1 Inhibits Human Breast Cancer <i>in Vivo</i> <b>Publ:</b> <u>Molecular Genetics and Metabolism</u> <b>Vol/Iss:</b> 63 <b>Pages:</b> 103-109 <b>Date:</b> 1998

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. See attached Kinds of U.S. Patent Documents. <sup>2</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>3</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	10/042,347
Filing Date	01/11/2002
First Named Inventor	O'Reilly et al.
Group Art. Unit	1642
Examiner Name	Sheela Jitendra Huff
Attorney Docket Number	05213-0880 (43170-249874)

Sheet 6 of 6

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	30	<b>Author:</b> XU, M. et al. <b>Title:</b> Parenteral Gene Therapy with p53 Inhibits Human Breat Tumors <i>In Vivo</i> Through a Bystander Mechanism Without Evidence of Toxicity <b>Publ:</b> Human Gene Therapy <b>Vol/Iss:</b> 8 <b>Pages:</b> 177-185 <b>Date:</b> 01/20/199	
	31	<b>Author:</b> ZABRENETZKY, V. et al. <b>Title:</b> EXPRESSION OF THE EXTRACELLULAR MATRIX MOLECULE THROMBOSPONDIN INVERSELY CORRELATES WITH MALIGNANT PROGRESSION IN MELANOMA, LUNG AND BREAST CARCINOMA CELL <b>Publ:</b> Int. J. Cancer <b>Vol/Iss:</b> 59 <b>Pages:</b> 191-195 <b>Date:</b> 1994	
	32	<b>Author:</b> ZHU, N. et al. <b>Title:</b> Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice <b>Publ:</b> Science <b>Vol/Iss:</b> 261 <b>Pages:</b> 209-211 <b>Date:</b> 07/09/199	

# RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.